PMU12 Cost-Benefit Analysis of Sodium Glucose Cotransporter-2 Inhibitor Use for Patients 65 Years with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.724
https://www.valueinhealthjournal.com/article/S1098-3015(21)00941-4/fulltext
Title :
PMU12 Cost-Benefit Analysis of Sodium Glucose Cotransporter-2 Inhibitor Use for Patients 65 Years with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00941-4&doi=10.1016/j.jval.2021.04.724
First page :
Section Title :
Open access? :
No
Section Order :
10235